Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene
Journal of Clinical Oncology · 20.12.2025 · 43 (36) · 3833-3843
DOI: 10.1200/jco-25-01114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.12.2025. Verfasst von Ninad Oak und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: DNA Repair, Genetic Predisposition to Disease, Osteosarcoma, DNA Damage. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Recent studies reveal that 5%-18% of children with cancer harbor pathogenic variants in known cancer-predisposing genes. However, DNA damage repair (DDR) genes, which are frequently somatically altered in pediatric tumors, have not been systematically examined as a source of novel cancer-predisposing signals. METHODS To address this gap, we interrogated 189 DDR genes for presence of germline predisposing variants (PV) among 5,993 childhood cancer cases and 14,477 adult noncancer controls (discovery cohort). PV were determined using a tiered approach incorporating ClinVar annotations, InterVar classification, and in silico tools (REVEL, CADD, and MetaSVM). Using logistic and firth regression, we identified genes with PV statistically enriched in the germline of children with tumors and replicated findings among 1,497 additional childhood cancer cases across three independent cohorts. RESULTS Analysis across all cases with cancer revealed enrichment of TP53 PV. Cancer-specific analyses confirmed known associations including germline TP53 PV in adrenocortical carcinoma, high-grade glioma (HGG), and medulloblastoma (MB), PMS2 in HGG and non-Hodgkin lymphoma (NHL), MLH1 in HGG, BRCA2 in NHL, and BARD1 in neuroblastoma. In addition, four novel associations were uncovered, including BRCA1 in ependymoma, SPIDR in HGG, SMC5 in MB, and SMARCAL1 in osteosarcoma (OS). Importantly, the SMARCAL1 :OS association was significant in the discovery (6/230, 2.6%, false discovery rate [FDR] logistic = 0.0189) as well as all three replication cohorts (Childhood Cancer Survivor Study: 8/275, 2.9%; P Fisher < .0001; Cancer Predisposition Syndrome-German Childhood Cancer Registry: 4/135, 3%, P Fisher = .002; Individualized Therapy for Relapsed Malignancies in Childhood: 4/217, 1.8%, P Fisher = .012). The remaining wild-type SMARCAL1 allele was deleted in three of four OS tumors with available data. CONCLUSION Our study confirms the relevance DDR genetic variation in pediatric cancer risk and establishes SMARCAL1 as a novel OS predisposing gene, providing insights into tumor biology and creating opportunities to optimize care for patients with this challenging tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
- Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN.
- Division of Computational Biology, Mayo Clinic, Rochester, MN.
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- German Cancer Consortium (DKTK), Heidelberg, Germany.
ORCID-Profile: Ninad Oak, Wenan Chen, Alise Blake, Lynn Harrison, Christopher Previti, Steffen Hirsch, Judith Penkert, Barbara C Jones, Michaela Nathrath, Kristian W Pajtler, David T W Jones, Olaf Witt, Uta Dirksen, Jiaming Li, Yadav Sapkota, Kirsten K Ness, Lillian M Guenther, Christian Kratz, Zhaoming Wang, Melissa M Hudson, Gang Wu, Kim E Nichols, Richa Sharma
Förderung
- NCI NIH HHS
Zitieren
APA
Oak, N., Chen, W., Blake, A., Harrison, L., O'Brien, M., Previti, C., Balasubramanian, G., Maass, K., Hirsch, S., Penkert, J., Jones, B. C., Schramm, K., Nathrath, M., Pajtler, K. W., Jones, D. T. W., Witt, O., Dirksen, U., Li, J., Sapkota, Y., …, & Sharma, R. (2025). Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene. Journal of Clinical Oncology, 43(36), 3833-3843. https://doi.org/10.1200/jco-25-01114
Vancouver
Oak N, Chen W, Blake A, Harrison L, O'Brien M, Previti C, et al. Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene. Journal of Clinical Oncology. 2025;43(36):3833-3843. doi:10.1200/jco-25-01114
BibTeX
@article{Oak2025,
author = {Oak, Ninad and Chen, Wenan and Blake, Alise and Harrison, Lynn and O'Brien, Martha and Previti, Christopher and Balasubramanian, Gnanaprakash and Maass, Kendra and Hirsch, Steffen and Penkert, Judith and Jones, Barbara C and Schramm, Kathrin and Nathrath, Michaela and Pajtler, Kristian W and Jones, David T W and Witt, Olaf and Dirksen, Uta and Li, Jiaming and Sapkota, Yadav and Ness, Kirsten K and Guenther, Lillian M and Pfister, Stefan M and Kratz, Christian and Wang, Zhaoming and Armstrong, Greg T and Hudson, Melissa M and Wu, Gang and Autry, Robert J and Nichols, Kim E and Sharma, Richa},
title = {Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {36},
pages = {3833--3843},
doi = {10.1200/jco-25-01114}
}
EUVIMED